Is Iterum Therapeutics Plc overvalued or undervalued?

As of 13 October 2023, Iterum Therapeutics Plc has moved from fair to attractive. The company is currently undervalued, with a price-to-earnings ratio of 12.5, a price-to-book ratio of 1.2, and a debt-to-equity ratio of 0.3. When compared to its peers, such as AcelRx Pharmaceuticals with a P/E ratio of 15.0 and Nabriva Therapeutics with a P/B ratio of 2.0, Iterum stands out as a more favorable investment option.
The recent performance of Iterum's stock has also been noteworthy, as it has outperformed the Sensex, reinforcing the attractiveness of its current valuation. Overall, the combination of strong ratios and favorable peer comparison suggests that Iterum Therapeutics Plc presents a compelling investment opportunity at this time.